{
    "organizations": [],
    "uuid": "e3d8bcf60e291c7be066f5554cfc62a7a256e63b",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-hansa-medical-granted-orphan-drug/brief-hansa-medical-granted-orphan-drug-designation-by-fda-idUSFWN1Q60FG",
    "ord_in_thread": 0,
    "title": "BRIEF-Hansa Medical Granted Orphan Drug Designation By FDA",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 16 (Reuters) - HANSA MEDICAL AB:\n* HANSA MEDICAL RECEIVES FDA ORPHAN DRUG DESIGNATION FOR IDES AND THE TREATMENT OF GUILLAIN-BARRÃ‰ SYNDROME Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-16T16:50:00.000+02:00",
    "crawled": "2018-02-17T14:41:54.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "hansa",
        "medical",
        "ab",
        "hansa",
        "medical",
        "receives",
        "fda",
        "orphan",
        "drug",
        "designation",
        "ides",
        "treatment",
        "syndrome",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}